We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Novel Biomarkers Found for Bowel Cancer Treatment

By LabMedica International staff writers
Posted on 03 Mar 2017
Bowel cancer is the third most common form of cancer in the world and 95% of cases are colorectal carcinomas and at an advanced stage they are one of the most common causes of death, as only some patients respond to drug treatment.

Colorectal carcinoma (CRC) represents a heterogeneous entity, with only a fraction of the tumors responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. More...
A consortium of scientists looked for biomarkers, molecules that are typical of the different tumor sub-groups and provide valuable information for diagnosis and potential treatment.

The OncoTrack consortium, a public-private consortium, has conducted one of Europe's largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. They recruited 106 CRC patients (stages I–IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totaling more than 4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumors, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumors and derived models provided a resource for advancing our understanding of CRC.

The consortium used various techniques to accomplish their goals, including growing tumors in tissue culture systems, as well as in special mouse strains, and subsequently treated with a range of medicaments. Through this, the scientists were able to better understand the relationships between the molecular pattern and the response of the tumor to drugs. Cancer relevant gene selection was done by taking the overlap with 31 significantly mutated genes in the CRC TCGA study and 86 genes recurrently mutated in CRC from the TCGA pan-cancer analysis. Paired-end libraries were sequenced on HiSeq 2,000/2,500 instruments with v3 chemistry.

The team discovered molecules that can predict the effectiveness of two drugs commonly used to treat this disease: Cetuximab, which inhibits the receptor for the epidermal growth factor (EGFR), and the chemotherapy drug 5FU. The scientists identified the genetic composition of the tumors and analyzed their so-called transcriptome, namely the set of all ribonucleic acid (RNA) molecules synthesized in a given tissue. Based on this analysis, they were able to produce a definite molecular fingerprint for all of the tumors.

Bodo Lange, PhD, CEO at Alacris Theranostics and a co-author of the study, said, “The extensive molecular and drug sensitivity datasets generated within this study are a highly valuable resource. Our findings provide major new insights into the molecular landscape of colorectal cancer, including the identification of novel alterations, which can be further exploited for advancing understanding of this lethal tumor type and for personalizing therapies.” The study was published on February 10, 2017, in the journal Nature Communications.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.